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Abstract 
Purpose: To study the pharmacokinetics and tissue distribution of N-3-methoxybenzyl-palmitamide 
(MPM) derived from Lepidium meyenii (Maca) 
Methods: MPM and N-benzylpalmitamide (BPM, as the internal standard, IS) were prepared by one-pot 
synthesis method and characterized. For the analysis of MPM in rat plasma and tissue samples, a rapid 
ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) 
method was developed and validated by optimizing sample preparation conditions and UPLC 
conditions. Finally, the pharmacokinetics and biodistribution of MPM after oral administration in rats 
were studied. 
Results: The lower limit of quantification (LLOQ) and limit of detection (LOD) of the UPLC-MS/MS 
method were 1.2 and 5.0 ng/mL, respectively. Good linear relationship of calibration curve (r > 0.9951) 
was achieved over the range of 5 – 5000 ng/mL. In pharmacokinetics, plasma concentration-time curve 
of MPM showed double peaks. The highest distribution of MPM after absorption was in the stomach, 
followed by lung. The absorption and eliminate rate of MPM were slow in rats. In fact, MPM displayed a 
lung targeting property. 
Conclusion: The developed UPLC-MS/MS method is suitable for plasma and tissue distribution studies 
of MPM in rats. The present study can provide guidance for the further development and utilization of 
Maca tuber. 
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Maca, an Andean plant of the crucifer family, is 
heavily cultivated in some South American 
countries, and is also called "Peruvian ginseng" 
[1]. Indigenous Peruvians have traditionally used 
Maca for centuries as an adaptogenic plant to 
manage infertility, anemia, menstrual, anticancer, 
female hormone balance and sexual disorders 
[1-3]. In recent years, Based on the historical use 
of above facts, a series of commercial dietary 
supplements containing Maca have gained 
popularity in Japan, Europe, the US and China 
[4]. Numerous secondary metabolites of the 
Maca have been found over the years, and 
macamide, one of the secondary metabolites, 
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was first found in Maca as the typical marker. On 
the chemical structure, macamide is composed 
of various fatty acids and their benzylamine. 
 
In recent years, macamide has been proposed to 
be the biologically active substance, because of 
its multiple functions, such as fatty acid amide 
hydrolase inhibitor [5], improving sexual 
performance [6], endurance capacity and anti-
fatigue [7]. So far, 22 kinds of macamide is 
separated and identified from Maca tuber, and N-
3-methoxybenzyl-palmitamide (MPM) is a 
representative substance [8,9]. 
 
In this study, MPM was further researched on its 
pharmacokinetics and tissue distribution in rats, 
in order to deepen the understanding of 
macamide, and to provide guidance for the 




Chemicals and reagents 
 
Palmitoyl chloride, benzylamine and 3-
Methoxybenzylamine were purchased from 
Sinopharm Chemical Reagent Co. Ltd., China. 
MPM and BPM (purity > 98.0 %) were 
synthesized in our laboratory. Their chemical 
structures are presented in Figure 1. Acetonitrile 
of high performance liquid chromatography 
(HPLC) grade was acquired from Merck KGaA 
(Darmstadt, Germany). The other solvents and 
chemicals were all of analytical reagent grade. 
The water (resistance > 18 MΩ) came from a 
Millipore Milli-Q water purification machine 
(Bedford, MA, USA). 
 
Synthesis of MPM and BPM 
 
Synthesis of MPM: Anhydrous diethyl ether (15 
mL) was placed to a round bottom flask which 
was attached to a Claisen adapter, and palmitoyl 
chloride (4.05 mL, 0.012 mol) was injected 
through the Claisen adapter septum. The mixture 
was stirred over 15 min in an ice bath. 
Subsequently, a mixture of 3-
Methoxybenzylamine (1.99 mL, 0.018 mol) and 
anhydrous diethyl ether (1.50 mL) was injected 
drop by drop into the reaction bottom flask, and 
then a white precipitate was formed at the end. 
The precipitate was washed with 10 % sodium 
hydroxide and 10 % hydrochloric acid. Finally, 
the product was recrystallized from ethanol with 
ca. 81 % yield. The spectroscopic data (UV, FT-
IR, ESIMS) of the product was characterized. 





Figure 1: Production mass spectra of (A) MPM and (B) BPM, and their chemical structures 
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Synthesis of BPM: BPM's synthesis process 
was the same with MPM, with benzylamine 
instead of 3-methoxybenzylamine [9]. 
 
Structure confirmation of MPM and BPM 
 
MPM: white powder; UV (MeOH solvent): λmax 
213, 273 nm; IR (KBr powder) cm-1: υmax 3294 
(N-H), 2919, 2849, 1640 (C=O), 1534, 1469, 
1261, 1154, 1049, 778, 693 cm-1; ESIMS, 
m/z376.4 ([M + H]+). 
 
BPM: white powder; UV (MeOH solvent): λmax 
209 nm; IR (KBr powder) cm-1: υmax3306 (N-H), 
2917, 2849, 1638 (C=O), 1550, 1458, 1248, 
1118, 1081, 744, 698 cm-1; ESIMS, m/z 346.3 
([M + H]+). The above structure data of MPM and 
BPM corresponded to data previously reported 
[9,10]. 
 
Instrumentation and conditions (for UPLC-
MS/MS method) 
 
Liquid chromatography was performed on an 
Acquity ultra performance liquid chromatography 
(UPLC) unit (Waters Corp., Milford, MA, USA) 
with an Acquity BEH C18 column (2.1 × 50 mm, 
1.7 μm particle size). The mobile phase 
consisted of acetonitrile and water containing 
0.05 % trifluoroacetic acid (TFA). A gradient 
elution program was conducted for 
chromatographic separation with 0.05 % TFA 
aqueous solution (mobile phase A) and 
acetonitrile (mobile phase B) as follows: 0 - 0.5 
min (30 % A), 0.5 - 2.0 min (30 - 10 % A), 2.0 - 
2.5 min (10 - 30 % A). The flow rate was 0.40 
mL/min and the overall run time was 2.5 min. 
 
A XEVO TQD triple quadruple mass 
spectrometer was used to carry out mass 
spectrometric analysis (Waters Corp.). Multiple 
Reaction Monitoring (MRM) mode is used in 
mass analyzers with an electro-spray ionization. 
The MRM transitions was m/z 376.4→120.9 and 
m/z 346.3→90.9 for MPM and IS, respectively. 
Data acquisition and instrument control adopted 




The method was fully validated for specificity, 
matrix effect, sensitivity, linearity, precision, 
accuracy, recovery and stability in accordance 
with the guidelines set by Food and Drug 
Administration of the United States [11]. Each 
validation run consisted of six replicates of 
quality control plasma samples (QC) or one set 
of calibration standards. 
 
The specificity was determined by analysis of 
blank plasma samples (or blank tissue samples), 
blank sample spiked and the plasma sample 
obtained after oral administration of MPM with six 
different rats. Moreover, the possible interference 
from endogenous substances was confirmed. To 
evaluate the matrix effect (ME) of blank plasma 
(or tissues), generalized standard addition 
method was performed. Six different blank rat 
plasma (or tissues) was spiked with the analytes. 
ME was calculated at three QC levels (10, 100 
and 1000 ng/mL) by comparing the peak areas 
(B/C × 100 %, B = the peak area of blank plasma 
samples (or tissues) spiked with analytes after 
extraction, C = the peak area of the pure 
standard solutions at the same concentrations). 
The ME of IS was calculated at the concentration 
(100 ng/mL) in a similar manner. 
The sensitivity of the method was evaluated by 
determination in terms of LLOQ, and signal-to-
noise ratio (SNR) was used to calculate the 
LLOQ. Calibration curves were obtained using 
these spiked calibration samples on three 
separate days in succession. Peak area ratio of 
MPM to IS was plotted against MPM 
concentrations. The correlation of all calibration 
curves was required more than 0.99. The 
precision and accuracy of the method were 
evaluated by analyzing the QC samples with 
known concentrations of MPM and IS (10, 100 
and 1000 ng/mL) with six replicates. The 
precision was defined by relative standard 
deviation (RSD), and the accuracy was 
presented as a relative error (RE). 
 
The extraction recoveries of MPM at three QC 
levels (10, 1000, 1000 ng/mL) were calculated by 
comparing peak area ratios of two different sets 
of samples. One was the samples spiked with 
the MPM prior to extraction, and the other was 
the samples spiked with the MPM after extraction 
at same content. The extraction recovery of IS 
was determined in the same manner. The 
stabilities of MPM in rat sample were analyzed 
by using six replicates of plasma samples spiked 
with MPM at known concentrations (10, 100 and 
1000 ng/mL). Those samples were exposed to 
following four conditions. They were respectively 
the short-term stability (exposing samples to 25 
°C for 24 h), the freeze–thaw stability (subjecting 
samples to five freeze–thaw cycles), the long-
term stability (samples stored at - 80 °C for 21 
days prior to extraction), and the processed 





The Sprague-Dawley rats (210 ± 20 g) were 
provided by the Laboratory Animal Center of 
Wenzhou Medical University, and were 
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performed to study the pharmacokinetics and 
biodistribution of MPM. Before the experiment, 
the diet was banned for 12 h, but the water was 
free. The animal care and use committee of our 
university approved the experiment protocols and 
procedures (ethical approval code: 
WMU20160817). These experiments are in line 
with rules in the NIH Guide for the Care and Use 




Six rats were used for pharmacokinetics study at 
a dose of 80 mg/kg MPM prepared with 1.0 % 
sodium carboxymethylcellulose. Collect whole 
blood (0.5 ml) from the caudal vein into plastic 
centrifuge tubes (pretreated with heparin sodium) 
at pre-dose, 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12, 
24 and 48 h after oral administration of MPM. 
Then the whole blood was centrifuged timely at 
3000 g for 10 min for isolation of the plasma. 
Those samples were stored at - 80 °C until 
further preparation. 
 
Tissue distribution studies 
 
Eighteen SD rats were randomly assigned to 
three groups with six rats per group. They were 
used for tissue distribution study at a dose of 
80mg/kg MPM prepared with 1.0 % sodium 
carboxymethylcellulose. Rats were sacrificed 
under ether anesthesia at 0.5, 2, 12 h after 
dosing and brain, lung, heart, stomach, kidney, 
liver, spleen or reproductive organ were 
harvested. All of the samples were timely stored 




The 250 µL plasma sample (or 0.25 g milled 
tissue sample) was added to a 5 mL centrifuge 
tube, and 5 µL of IS methanol solution (5 μg/mL) 
and 2 × 2.5 mL ethanol solution (containing 0.2 
% formic acid) was added. Then the tubes were 
vortexed for 1.0 min and centrifuged at 5,000 g 
for 10 min. The twice extracted solutions were 
merged and concentrated. It was purified by pure 
silica solid-phase extraction (SPE) column 
washed with 2 × 1 mL of water, 1 mL of 
acetonitrile – water (20 : 80, v/v) and finally with 
3 × 1 mL of acetonitrile, and the eluate was blow-
dried with nitrogen at 50 °C and the residue was 
redissolved in 250 µL of ethanol. This extracted 




After UPLC/MS determination, the peak areas of 
analytes were integrated, and the peak area ratio 
of MPM to IS was calculated. Parameter values 
were calculated and expressed with mean ± SD 
(upper and lower CI 95 %). Precision RSD (%) = 
SD/mean × 100. Accuracy RE (%) = (conc. 




Optimized sample preparation and UPLC 
conditions 
 
Extract reagent played a critical role when the 
sample was prepared to get higher recovery and 
lower matrix interferences for the analyte. The 
reagent effect on extraction yield was 
investigated, including methanol, alcohol, 
acetonitrile, acetone and n-hexane. In order to 
study the effect of pH, each of these solvents 
added 0.2 % formic acid and 0.2 % ammonia 
respectively. Ethanol solution (containing 0.2 % 
formic acid) had the highest recovery rate, but 
also had a high matrix interference especially in 
tissue sample. In order to remove the matrix 
interference, SPE method was adopted, and it 
was valid that plasma sample and tissue sample 
all had negligible matrix interference. 
 
To achieve more efficient separation of isolates, 
chromatographic conditions of chromatographic 
column and mobile phase were optimized. We 
investigated four mobile phases, and acetonitrile 
- water (containing 0.05 % TFA) resulted in the 
production of better peaks due to higher 
sensitivities. Furthermore, We tested three types 
of chromatographic column with different polarity. 
Finally Acquity BEH C18 column (2.1 × 50 mm, 
1.7 μm particle size) produced better separation 
within a short time. In addition, we optimized 
mobile phase gradient elution with acetonitrile - 
water containing 0.05 % TFA in 400 μL/min flow 
rate, within 2.5 min. 
 
Specificity and matrix effect 
 
Three samples of the representative extract ion 
chromatograms (XIC) from mass spectrometry 
were shown in Figure 2. Three samples of blank 
plasma sample, plasma sample spiked at LLOQ 
level and plasma sample collected 15 min after 
oral administration represented three different 
concentrations, and endogenous interferences 
for the analyte were all not observed. The matrix 
effect for MPM at concentrations of 10, 100 and 
1000 ng/mL, were 95.1 ± 3.7 %, 106.4 ± 4.2 % 
and 102.7 ± 4.3 % (n=6), respectively. The ME 
for IS (100 ng/mL) was 105.3 ± 3.6 % (n=6). It 
followed that matrix effect from plasma was 
negligible in this method. 
 
The use of SPE method resulted in a significant 
reduction of endogenous interferences of tissue 
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samples. The extract ion chromatograms of 
tissue sample were similar to the plasma 
samples'. 
 
Linearity and sensitivity 
 
Using weighted (1/x2) linear regression analysis, 
we established calibration curves based on the 
peak area ratio of MPM to IS. MPM presented a 
good linear relationship with the range of 5 - 
5000 ng/mL. The regression equations, the linear 
ranges, and the correlation coefficients for MPM 
in plasma and tissues are listed in Table 1. The 
LLOQ of MPM in plasma and tissue was 5 ng/mL 
with the RSD and RE of 8.5 and 5.6 %, 
respectively. The LOD of MPM in plasma and 
tissues was 1.2 ng/mL. 
 
Precision, accuracy and recovery 
 
RSD taken as the measures of precision for QCs 
was calculated over three days of validation tests 
at three concentration levels. In the same way, 
relative error (RE) was taken as the measures of 
accuracy. The results of the precision, accuracy 
and recovery were showed in Table 2. All results 
of precision for the samples were in the range of 
- 9.2 ~ 11.8 % within the acceptable criteria of ± 
15 %. These data demonstrated that the assay 
was reproducible and accurate for MPM 
determination in rat plasma or tissue samples. 
 
Figure 2: Representative XIC from mass spectrometry: (A) a blank plasma sample; (B) plasma 
sample spiked at LLOQ level; (C) plasma sample collected 15min after oral administration of MPM at 
the dose of 80mg/kg. The XIC showed MPM at m/z 376.4 → 120.9 and IS at m/z 346.3 → 90.9 
 
Table 1: Calibration parameters for MPM in rat plasma and tissues 
 
Sample Regression equation Correlation coefficient (r) 
Linear range 
（ng/mL） 
Plasma y = 0.0001562321x + 0.00024597 0.9969 5 - 5000 
Brain y = 0.0001610634x + 0.00032861 0.9991 5 - 5000 
Lung y = 0.0001547624x + 0.00021632 0.9951 5 - 5000 
Heart y = 0.0001496412x + 0.00023037 0.9959 5 - 5000 
Stomach y = 0.0001595638x + 0.00019053 0.9977 5 - 5000 
Kidney y = 0.0001475628x + 0.00020531 0.9969 5 - 5000 
Liver y = 0.0001555281x + 0.00029651 0.9992 5 - 5000 
Spleen y = 0.0001630921x + 0.00017976 0.9987 5 - 5000 
Reproductive 
organ y = 0.0001450331x + 0.00013992 0.9971 5 - 5000 
Note: y = the peak area ratio of MPM to IS; x = the concentration of MPM 
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Table 2: Precision, accuracy and recovery for the determination of MPM in rat sample (n = 6) 
 
Sample Conc. spiked  (ng/mL) 
RSD (%) RE (%) Recovery 
(%) intra-day inter-day intra-day inter-day 
Plasma 10 10.1 10.6 -8.6 7.8 82.3 
 100 5.5 6.1 6.7 5.5 87.8 
 1000 2.6 3.2 2.4 -3.3 85.1 
Brain 10 9.3 11.2 -8.2 9.2 80.3 
 100 6.0 6.4 6.2 -6.0 81.5 
 1000 3.2 3.6 2.7 -3.2 86.2 
Lung  10 9.2 10.1 -8.7 7.9 80.9 
 100 5.1 6.3 7.2 -6.8 83.8 
 1000 3.9 2.8 2.1 -2.9 84.2 
Heart 10 8.7 10.3 -9.2 8.3 82.1 
 100 6.6 6.1 7.8 -5.7 88.8 
 1000 2.1 3.7 3.0 -3.2 85.2 
Stomach 10 10.5 12.3 -9.1 8.6 90.4 
 100 6.5 5.1 7.3 6.7 84.8 
 1000 3.9 4.1 3.6 -3.1 87.2 
Kidney 10 9.7 9.6 -3.2 7.3 80.9 
 100 5.1 6.5 7.8 -5.3 85.8 
 1000 4.9 3.6 2.7 -3.9 84.1 
Liver 10 9.5 10.2 -8.2 7.4 83.4 
 100 5.9 6.4 5.9 5.8 83.8 
 1000 2.3 3.7 2.8 -3.3 84.7 
Spleen 10 9.9 9.8 -8.0 7.7 91.4 
 100 5.4 5.7 5.5 5.4 85.8 
 1000 3.0 3.2 4.6 -3.7 85.2 
Reproductive  10 9.9 11.8 -8.4 9.2 87.1 
organ 100 6.5 7.3 6.8 -6.9 82.4 
 1000 3.9 3.9 -4.7 4.8 83.1 
 
In rat plasma and tissue samples, the minimum 
recovery of MPM was 80.3 %. The recovery of 
the IS (100 ng/mL) was 83.7 % or higher. The 
above results indicated that sample preparation 
method could obtain satisfying extraction 





The stability of MPM in rat sample were 
evaluated by analyzing six replicates of rat 
samples which were all exposed to long-term 
stability, short-term stability freeze–thaw stability, 
and the processed sample stability. The re-
inspection yield {RIY = (conc. measured 
later/conc. measured first) × 100 %} was used to 
express the stability. Calculated results showed 
that the RIY was in the range of 90.5 – 111.2 %. 
The data indicated that there was no significant 
degradation and the established methods were 
acceptable when samples of MPM were exposed 
to different conditions. The method was 
successfully applied to determine the 
concentration of MPM in rat’s plasma and tissue 




The mean plasma concentration-time profile is 
shown in Figure 3 and the primary 
pharmacokinetic parameters are summarized in 
Table 3. Plasma concentration-time curve of 
MPM showed double peaks. The peak plasma 
concentration of MPM after oral administration at 
0.5 h was 600.3 ± 167.1 ng/mL. The area under 
the curve (AUC0→t) and elimination half-life of 
MPM in plasma was 6485.75 ± 737.72 ng/mL•h 




The tissue distribution of MPM in rats after oral 
administration of 80 mg/kg dose is presented in 
Figure 4. The MPM concentrations in stomach 
after 0.5, 2 and 12 h were 3105.0 ± 267.1, 
2782.2 ± 205.6 and 404.5 ± 53.1 ng/g, 
respectively. The MPM concentrations in lung 
were 300.5 ± 17.4, 2200.7 ± 152.9 and 415.2 ± 
43.3 ng/g, respectively. The MPM concentrations 
in spleen were 205.3 ± 15.8, 769.3 ± 94.1 and 
175.2 ± 24.1 ng/g, respectively. The MPM 
concentration in other tissues of brain, heart, 
kidney, liver, reproductive organ was low, and 
even its highest concentration also was under 




MPM is a hydrophobic organic compound with a 
long aliphatic chain. Usual method to prepare 
biological sample with adding 200 µL methanol 
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or acetonitrile to100 µL plasma sample was tried 
and infeasible because of the low recovery rate. 
Several kinds of reagents with different volume 
were investigated. Finally, high proportion of 
extracting solution and addition of formic acid 
were adopted together, to raise the extraction 
rate and recovery rate of MPM. The optimum 
combination ratio was 1 : 20 (v : v) corresponding 
to biological sample : ethanol (containing 0.2 % 
formic  acid). 
 
 
Figure 3: Mean plasma concentration-time plots 
at a single dose of 80 mg/kg MPM of oral 
administration in rats (n = 6) 
 
Table 3: The main pharmacokinetic parameters 
at a single dose of 80 mg/kg MPM of oral 
administration in rats (n = 6) 
 
Parameter Mean ± SD 
Absorption  
Tmax (h) 0.50 ± 0.18 
Cmax (ng/mL) 600.3 ± 167.1 
Elimination  
T1/2el (h) 7.44 ± 1.12 
AUC0→t (ng/mL•h) 6485.75 ± 737.72 
AUC0→∞ (ng/mL•h) 6560.91 ± 807.36 
Vd (L/kg) 130.98 ± 15.29 
CL (L/h/kg) 12.19 ± 1.92 
 
In pharmacokinetic experiment, plasma 
concentration-time curve of MPM presented a 
double peak, probably because the rat's 
organization concentration of MPM is much 
higher than its plasma's, which could cause MPM 
from organization transporting to plasma [13]. 
We inferred there might be distribution, re-
absorption and entero-hepatic circulation in rats 
[14]. Pharmacokinetic of MPM could be 
evaluated by two compartment model. The 
elimination half-life of 7.44 ± 1.12 h showed that 
the elimination of MPM was slow in rats.  
 
 
Figure 4: Rat tissue concentration of MPM after 
single oral administration of 80 mg/kg dose 
 
The value of AUC (6485.75 ± 737.72 ng/mL•h) is 
not significant with a dose of 80 mg/kg compared 
to other reported drugs [15-17]. Unfortunately, 
there are missing data of absolute bioavailability, 
because direct intravenous drug delivery was 
unsuccessful in this experiment. By intravenous 
administration of MPM ethanol solution (at the 
dose of 1 mg/kg MPM), all the rats died within 5 
min. After excluding the toxicity of the MPM [18], 
the poor solubility of MPM in blood that could 
lead MPM to precipitating and blocking the blood 
vessels might be the main cause of death of the 
rats. 
 
The results of tissue distribution showed that 
stomach had the dominant distribution, and that 
the absorption of MPM in stomach was slow and 
incomplete because of a higher concentration at 
12 h after dosing. The second was in lung with 
relatively high concentration, even higher than 
the concentration of stomach at the point of 12 h. 
The phenomenon showed that MPM in lung was 
eliminated at a slow rate. Lipophilic MPM could 
remained in lung tissue with a longer time, 
because lung tissue has good lipophicity [13]. 
Thus, MPM has a high targeting property and is 





The developed UPLC-MS/MS method is suitable 
for plasma and tissue distribution studies of MPM 
in rats. The MPM pharmacokinetic and tissue 
distribution data obtained would provide 
guidance for the further development and 
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